EMA Adopts a New Pharmaceutical Form of Selumetinib By Ogkologos - December 16, 2025 427 0 Facebook Twitter Google+ Pinterest WhatsApp It is associated with an extension to the existing indication Source RELATED ARTICLESMORE FROM AUTHOR Comprehensive Genomic Profiling with Subsequent Molecularly Guided Therapy Improves Outcomes Over Platinum-based Chemotherapy in Previously Untreated, Unfavourable CUP NCI and CRUK Take on Cancer’s Toughest Problems Tebentafusp Continues to Provide Long-Term OS Benefit in Previously Untreated Patients with Unresectable or Metastatic Uveal Melanoma MOST POPULAR 如果您剛確診為肺癌患者，請來看看專家的回答 April 22, 2021 More than 65,000 people are left waiting to find out if... May 8, 2022 EMA Adopts a New Pharmaceutical Form of Selumetinib December 16, 2025 Promising pCR Rates with Neoadjuvant Durvalumab Plus Platinum-based Chemotherapy Combined with... July 29, 2025 Load more HOT NEWS ΚΑΡΚΙΝΟΣ ΧΟΛΗΔΟΧΟΥ ΚΥΣΤΕΩΣ FDA Approves Pembrolizumab with Enfortumab Vedotin-ejfv for Muscle Invasive Bladder Cancer The Cancer Moonshot: A Midpoint Progress Update Breastfeeding Patterns and Relation to Breast Cancer Outcomes After Early, Hormone...
